Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

cAMP-dependend plasticity of striatal projection neurons in health and disease

Project description

Second-messenger effects on neuronal plasticity and implications for Parkinson’s disease

Cyclic adenosine monophosphate is a ubiquitous so-called second messenger in the body, a molecule that transduces a signal and initiates other events or processes like a runner passing a baton. Its role in the functioning of the nervous system is well accepted. However, whether it plays a role in the synaptic and structural plasticity of dopaminergic neurons in the striatum, integrally involved in Parkinson’s disease, is not known. With the support of the Marie Skłodowska-Curie Actions programme, the SCAMPICITY project is seeking to answer this open question with a focus on spiny projection neurons in the striatum.

Objective

The project aims to reveal the so far unknown role of cAMP in structural and synaptic plasticity of striatal spiny projection neurons (SPNs) in health and disease. Striatal SPNs divide into two subgroups: the dSPNs and iSPNs. While dSPNs preferentially express the D1 dopamine (DA) receptor, iSPNs express the D2 receptor. Both are coupled to the cAMP second messenger cascade, however the D1-receptor activates and the D2-receptor inhibits it. DA has therefore opposite effects on the two SPN groups, both mediated by cAMP. Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It is characterized by typical motor symptoms caused by the death of DA neurons and the subsequent lack of DA in the striatum. A long-standing but untested notion in the field is that loss of DA leads to aberrant cAMP levels and signaling in SPNs.
The project will look at the role of cAMP in SPN synaptic and structural plasticity. We will use novel optogenetic tools that allow cell-type specific activation of cAMP, with high spatiotemporal resolution. Focusing on corticostriatal synaptic transmission, we want to ask if transient activation of cAMP alone is sufficient to induce plasticity (e.g. strengthening or weakening) of this synapse. Secondly, we will use known plasticity protocols and test if precise activation of cAMP can interrupted or potentiated them. Unpublished data suggest that in vivo drug treatments that presumably elevate cAMP in SPNs induce structural plasticity, i.e. loss of dendritic spines. Following this we will unravel if cell-type specific activation of cAMP is sufficient to induce structural changes and how this relates to synaptic plasticity. Lastly, we will test the long-standing notion that cAMP levels and the responsiveness of the cascade are altered in an animal model of PD. This project will advance our understanding of how SPNs work by unraveling cAMP’s role in plasticity, and potentially inform future strategies to combat PD.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF-EF-ST - Standard EF

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Net EU contribution
€ 174 806,40
Address
Martinistrasse 52
20251 Hamburg
Germany
Region
Hamburg Hamburg Hamburg
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 174 806,40